Recommandations en Onco-Urologie 2010 : Tumeurs germinales du testicule

25 novembre 2010

Auteurs : X. Durand, J. Rigaud, C. Avances, P. Camparo, S. Culine, F. Iborra, N. Mottet, P. Sèbe, M. Soulié, les membres du CCAFU
Référence : Prog Urol, 2010, 20, S297, suppl. S4




 



Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser



Références



Mottet N., Culine S., Iborra F., Avances C., Bastide C., Lesourd A., et al. Tumeurs du testicule : Recommandations 2007 en oncourologie Prog Urol 2007 ;  17 : 1035-1045 [cross-ref]
Germa-Lluch J.R., Garcia del Muro X., Maroto P., Paz-Ares L., Arranz J.A., Guma J., et al. Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis : the experience of the Spanish Germ-Cell Cancer Group (GG) Eur Urol 2002 ;  42 : 553-562discussion 562-53.
Walschaerts M., Huyghe E., Muller A., Bachaud J.M., Bujan L., Thonneau P. Doubling of testicular cancer incidence rate over the last 20 years in southern France Cancer Causes Control 2008 ;  19 : 155-161 [cross-ref]
Tsili A.C., Argyropoulou M.I., Giannakis D., Sofikitis N., Tsampoulas K. MRI in the characterization and local staging of testicular neoplasms AJR Am J Roentgenol 2010 ;  194 : 682-689 [cross-ref]
Heidenreich A., Weissbach L., Holtl W., Albers P., Kliesch S., Kohrmann K.U., et al. Organ sparing surgery for malignant germ cell tumor of the testis J Urol 2001 ;  166 : 2161-2165 [cross-ref]
Classen J., Dieckmann K., Bamberg M., Souchon R., Kliesch S., Kuehn M., et al. Radiotherapy with 16 Gy may fail to eradicate testicular intraepithelial neoplasia : preliminary communication of a dose-reduction trial of the German Testicular Cancer Study Group Br J Cancer 2003 ;  88 : 828-831 [cross-ref]
International Germ Cell Consensus Classification : a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15: 594-603.
De Santis M., Becherer A., Bokemeyer C., Stoiber F., Oechsle K., Sellner F., et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma : an update of the prospective multicentric SEMPET trial J Clin Oncol 2004 ;  22 : 1034-1039 [cross-ref]
Warde P., Specht L., Horwich A., Oliver T., Panzarella T., Gospodarowicz M., et al. Prognostic factors for relapse in stage I seminoma managed by surveillance : a pooled analysis J Clin Oncol 2002 ;  20 : 4448-4452 [cross-ref]
Albers P., Siener R., Kliesch S., Weissbach L., Krege S., Sparwasser C., et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors : results of the German Testicular Cancer Study Group Trial J Clin Oncol 2003 ;  21 : 1505-1512 [cross-ref]
Aparicio J., Garcia del Muro X., Maroto P., Paz-Ares L., Alba E., Saenz A., et al. Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant singleagent carboplatin for patients with clinical stage I seminoma Ann Oncol 2003 ;  14 : 867-872 [cross-ref]
Oliver R.T., Mason M.D., Mead G.M., von der Maase H., Rustin G.J., Joffe J.K., et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma : a randomised trial Lancet 2005 ;  366 : 293-300 [cross-ref]
Jones W.G., Fossa S.D., Mead G.M., Roberts J.T., Sokal M., Horwich A., et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma : a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328) J Clin Oncol 2005 ;  23 : 1200-1208 [cross-ref]
Albers P. Management of stage I testis cancer Eur Urol 2007 ;  51 : 34-43discussion 43-34.
Heidenreich A., Albers P., Hartmann M., Kliesch S., Kohrmann K.U., Krege S., et al. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis : experience of the German Testicular Cancer Study Group J Urol 2003 ;  169 : 1710-1714 [cross-ref]
Oliver R.T., Ong J., Shamash J., Ravi R., Nagund V., Harper P., et al. Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy Urology 2004 ;  63 : 556-561 [inter-ref]
Bohlen D., Burkhard F.C., Mills R., Sonntag R.W., Studer U.E. Fertility and sexual function following orchiectomy and 2 cycles of chemotherapy for stage I high risk nonseminomatous germ cell cancer J Urol 2001 ;  165 : 441-444 [cross-ref]
Albers P., Siener R., Krege S., Schmelz H.U., Dieckmann K.P., Heidenreich A., et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors : AUO trial AH 01/94 by the German Testicular Cancer Study Group J Clin Oncol 2008 ;  26 : 2966-2972 [cross-ref]
Rassweiler J.J., Scheitlin W., Heidenreich A., Laguna M.P., Janetschek G. Laparoscopic retroperitoneal lymph node dissection : does it still have a role in the management of clinical stage I nonseminomatous testis cancer ? A European perspective Eur Urol 2008 ;  54 : 1004-1015
Cullen M.H., Stenning S.P., Parkinson M.C., Fossa S.D., Kaye S.B., Horwich A.H., et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis : a Medical Research Council report J Clin Oncol 1996 ;  14 : 1106-1113 [cross-ref]
Chevreau C., Mazerolles C., Soulie M., Gaspard M.H., Mourey L., Bujan L., et al. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion Eur Urol 2004 ;  46 : 209-214discussion 214-205.
 [cross-ref]
Tandstad T., Dahl O., Cohn-Cedermark G., Cavallin-Stahl E., Stierner U., Solberg A., et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer : the SWENOTECA management program J Clin Oncol 2009 ;  27 : 2122-2128 [cross-ref]
Kondagunta G.V., Sheinfeld J., Mazumdar M., Mariani T.V., Bajorin D., Bacik J., et al. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy J Clin Oncol 2004 ;  22 : 464-467 [cross-ref]
Culine S., Kerbrat P., Kramar A., Theodore C., Chevreau C., Geoffrois L., et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors : a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP) Ann Oncol 2007 ;  18 : 917-924 [cross-ref]
Frohlich M.W., Small E.J. Stage II nonseminomatous testis cancer : the roles of primary and adjuvant chemotherapy Urol Clin North Am 1998 ;  25 : 451-459 [inter-ref]
Motzer R.J., Nichols C.J., Margolin K.A., Bacik J., Richardson P.G., Vogelzang N.J., et al. Phase III randomized trial of conventional- dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as firstline treatment for patients with poor-prognosis metastatic germ cell tumors J Clin Oncol 2007 ;  25 : 247-256 [cross-ref]
Schwartz L.H., Bogaerts J., Ford R., Shankar L., Therasse P., Gwyther S., et al. Evaluation of lymph nodes with RECIST 1.1 Eur J Cancer 2009 ;  45 : 261-267 [cross-ref]
Oechsle K., Hartmann M., Brenner W., Venz S., Weissbach L., Franzius C., et al. [18F] Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy : the German multicenter positron emission tomography study group J Clin Oncol 2008 ;  26 : 5930-5935 [cross-ref]
Kollmannsberger C., Daneshmand S., So A., Chi K.N., Murray N., Moore C., et al. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery J Clin Oncol 2010 ;  28 : 537-542 [cross-ref]
Fossa S.D., Borge L., Aass N., Johannessen N.B., Stenwig A.E., Kaalhus O. The treatment of advanced metastatic seminoma : experience in 55 cases J Clin Oncol 1987 ;  5 : 1071-1077 [cross-ref]
Fizazi K., Tjulandin S., Salvioni R., Germa-Lluch J.R., Bouzy J., Ragan D., et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors : prognostic factors and role of postsurgery chemotherapy - - results from an international studygroup J Clin Oncol 2001 ;  19 : 2647-2657 [cross-ref]
Miller K.D., Loehrer P.J., Gonin R., Einhorn L.H. Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma J Clin Oncol 1997 ;  15 : 1427-1431 [cross-ref]
Oldenburg J., Fossa S.D. Late relapse of nonseminomatous germ cell tumours BJU Int 2009 ;  104 : 1413-1417 [cross-ref]
Kondagunta G.V., Bacik J., Donadio A., Bajorin D., Marion S., Sheinfeld J., et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors J Clin Oncol 2005 ;  23 : 6549-6555 [cross-ref]
Albers P., Ganz A., Hannig E., Miersch W.D., Muller S.C. Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers J Urol 2000 ;  164 : 381-384 [cross-ref]
George D.W., Foster R.S., Hromas R.A., Robertson K.A., Vance G.H., Ulbright T.M., et al. Update on late relapse of germ cell tumor : a clinical and molecular analysis J Clin Oncol 2003 ;  21 : 113-122 [cross-ref]
Schmoll H.J., Jordan K., Huddart R., Laguna M.P., Horwich A., Fizazi K., et al. Testicular non-seminoma : ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 2009 ;  20 : 89-96
Rustin G.J., Mead G.M., Stenning S.P., Vasey P.A., Aass N., Huddart R.A., et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis : Medical Research Council Trial TE08, ISRCTN56475197 - -the National Cancer Research Institute Testis Cancer Clinical Studies Group J Clin Oncol 2007 ;  25 : 1310-1315 [cross-ref]






© 2010 
Elsevier Masson SAS. Tous droits réservés.